Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO-3 FLT201 gene therapy trial in Gaucher disease type 1
2025-520765-50-00Phase 3Authorised
- Sponsor
- Spur Therapeutics
- Start
- Sep 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of avigbagene parvec in Gaucher disease type 1 (GD1), sponsored by Spur Therapeutics. Primary endpoint: Stable hemoglobin concentration at Week 52. Planned start Sep 2026; status: authorised.
02
Drugs
avigbagene parvec
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2025-520765-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520765-50-00.